Anixa Biosciences Establishes Cancer Business Advisory Board
TW's Take: this is a very strong group of individuals. Hopefully the establishment of this board leads to a meaningful partnership on one or...
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
TW's Take: enrollment is finally picking up and the therapy has shown an excellent safety profile and some moderate efficacy at the initial, sub-therapeutic...
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual...
TW's Take: more scientific validation for this unique therapy provides further evidence of a potentially blockbuster solid-tumor cancer platform.
SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa...
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest...
TW's Take: my thinking behind this "news story" is that management is frustrated by the lack of value being assigned to the company in...
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine...
TW's Take: this trial will have meaningful results in December which could be the closest game-changing event for Anixa. Very exciting opportunity that the...
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
TW's Take: this program has great potential and is overlooked by the market, but is very early stage so not really impactful to today's...
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
TW's Take: the company continues to build their patent portfolio while we await more data from the program. Hopefully we will learn more in...
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
TW's Take: nice to see this program gaining some momentum. Due to changes in their recruitment process, expect to see enrollment accelerate and results...
Recapping Anixa…Premium Subscriber Update
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast...
TW's Take: very positive data from this program. Market continues to under-appreciate this company and its data.
SAN JOSE, Calif. -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a...
Anixa’s Breast Cancer Vaccine Looks Spot On…An Interview With Dr. Amit Kumar
Tailwinds Research (TW) – Your presentation at AACR looked impressive, but how should investors interpret the data?
Dr. Amit Kumar (AK) – In this first...
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual...
TW's Take: looking forward to seeing the results of this breakthrough vaccine which should be a major catalyst for Anixa.
SAN JOSE, Calif., March 27, 2023 /PRNewswire/...
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine...
TW's Take: all systems go for the vaccine as we await key data in April that should be the catalyst for shares of ANIX.
SAN...
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
TW's Take: an impressive board of individuals who likely believe in the future success of this vaccine if they are lending their name to...
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
TW's Take: nice to see that phase 1a is on track to present data in Q2 of next year. This will be a significant...
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio...
TW's Take: this trial continues to run ahead of expectations and increased awareness will position ANIX for a strong move into data in 2023.
SAN...
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss...
TW's Take: the scientific community is getting increasingly excited about Anixa's CAR-T treatment as demonstrated by its upcoming presentations at important conferences.
SAN JOSE, Calif., Oct....
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at...
TW's Take: Anixa's Breast Cancer Vaccine program moving into phase 1b this quickly is definitive proof that they have seen excellent results so far....
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for...
TW's Take: with the first patient showing stable disease and great safety data, this program is certainly off to a great start. Potential blockbuster...
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center &...
TW's Take: we are very excited to learn more about this program and this event could be a very nice catalyst for the stock.
SAN...
CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa
TW Research (TW) - First off, congrats on dosing your first patient in your Ovarian cancer trial. It took a lot longer than expected...
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
TW's Take: very exciting news as Anixa now has a second potentially blockbuster program in the clinic. CER-T results are expected to be released...
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
TW's Take: Anixa continues to move this program forward. Expect compelling data from the ongoing phase 1 trial sometime late in 2022.
SAN JOSE, Calif., July...
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research...
TW's Take: on the back of their breast cancer vaccine trial, which is seeing excellent early results, Anixa's ovarian cancer vaccine could be their...
Going Downhill
This past weekend I spent mountain biking in Downieville. Our group gets shuttled up to the top of the mountain and then careen down...
High Degree of Confidence
This week I'm writing my newsletter on Thursday as I'm heading out to California this afternoon. The upcoming weekend will be spent in Downieville,...
CEO Knows Best
The saying about insider stock transactions goes like this, "there are many reasons for insiders to sell but only one reason for them to...
Stepping on Rakes
Last week was the second week in a row where the TW portfolio was basically unchanged. A sign that markets are calming down? Actually,...
The Rolling Correction Gathers Steam…
Thus endeth the worst month for the stock market since March of 2020. Friday's meltdown took the S&P to -9% for the month. It's...
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of...
TW's Take: quite positive that this trial is getting attention from ASCO, the preeminent cancer meeting. We believe Cleveland Clinic is likely to also...
It’s A Process
This past week in Charlottesville, The Boar's Head Women's Open took place. This is an annual tennis tournament featuring 32 professional tennis players, most...
Anixa Zoom Recap
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop...
TW's Take: nice to see Moffitt getting more aggressive in taking this novel solid tumor CAR-T treatment out to the medical community. Success here...
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at...
TW's Take: Finally!!! Great news that this trial has been given the go-ahead from the FDA. Possibly revolutionary for treatment of solid tumors as,...
Groundhog Day
Another week in the market, another leg down. Some pundits are saying we are now entering a bear market. Those of us who invest...
ANIX Update
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
TW's Take: Covid is here to stay and Anixa is showing excellent early stage results in a program that has cost very little to...
ParkerVision’s Time is Nigh…
Knock me over with a feather but there's finally been some movement in the ParkerVision (PRKR) vs. Qualcomm (QCOM) trial in Orlando. This is...
Welcome to 2022?
So much for thinking 2022 was going to be an improvement over last year. Last Sunday I tested positive for covid then, on Monday,...
Happy New Year!!!
Investing in micro-cap stocks with a 3-5 year time horizon, which is my expectation for a holding period every time I enter a position,...
Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective...
TW's Take: this program continues to make solid, albeit early-stage, progress. Covid isn't going away and Anixa has an opportunity here long-term.
SAN JOSE, Calif....
Bottom Picking
My constant refrain for most of 2021 has been that I don't like the market but love the stocks in my portfolio. I can...
Turkey Shoot…December Preview
Well, that didn't last long, did it? On Tuesday and Wednesday we saw what looked like a great reversal for biotech. The XBI opened...
Asymmetric Risk
Intelligent investing can truly be boiled down to the understanding of risk and reward. In order to properly assess the potential risks of an...
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative...
TW's Take: exciting news for Anixa and for women as the first ever vaccine for breast cancer trial has launched. We believe that this...
Training My Thoughts
Rode the train up to DC from Charlottesville on Friday night and, let me tell you, despite all the years and money thrown at...
Saturday Morning Musings
In a slow week for news from our universe of companies, the biggest news was from TFF Pharma (TFFP) which announced pre-clinical success of...
$8 Paddle Balls?
The markets had a nice bounce late last week. This was sparked by the government getting its act together enough to kick the debt...
Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology
TW's Take: patent protection in China is an unexpected surprise. We are looking forward to seeing the company begin both their human trials during...
October Awaits
September to remember? I had such high hopes. Sadly, it turned out to be a very forgettable month and I'm happy to have it...
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
TW's Take: a positive that this patent helps broaden coverage of the technology in other cancers besides ovarian. If this CAR-T therapy proves effective,...
When The Tide Goes Out, You See Who’s Swimming Naked…
The markets had another downward-trending week since the last newsletter. However, the overall tone of the market felt better from a micro-cap investing standpoint...
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for...
TW's Take: as this promising treatment moves into the clinic later this year, there will be increased attention paid to Anixa and their partner,...
Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
TW's Take: Nice to see Dr. Kumar begin to build out the team around himself. Anixa is about to get very busy with two...
A September To Remember?
I read this week where someone said, "the short story is always sexier." There's certainly a lot of truth in that. Here in September...
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of...
TW's Take: great news that will allow this exciting program to start human trials sometime in the next 6 months (hopefully by year-end).
SAN JOSE,...
Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant
TW's Take: while this program is still in the early stages of development, this demonstrates they are heading in the right direction with their...
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology
TW's Take: an exciting early stage program with a world-class partner. The risk/reward of Anixa is very skewed to the positive at current valuations.
SAN...
Are We Having Fun Yet? Bull Ride Continues
The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...
July About to Close With a Bang?
Last week wasn't a bad week for the markets at all. With a nice two day rally to end the week, the Russell 2000...
Back In The Torture Chamber
With the S&P 500 hitting new highs recently, continuing the rally from last March's lows, we are all having a great time, right? Uhhh,...
Let’s Get Ready To Rumble (2nd Half Preview)
To steal a line from Charles Dickens, "It was the best of times. It was the worst of times. Then it was pretty darn...
Hoping for Fireworks
As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is...
Stock Picking Wins This Week
It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed...
TW's Take: nice to see the support for this early stage program from the NIH.
SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc....
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for...
TW's Take: this is close to the best possible news Anixa could have asked for. It appears they will definitely be dosing their first...
Gas Lines and Inflation…Is This The 80’s?
This past week saw yet another ugly market for micro-caps as the whole investment community seems to be increasingly worried about inflation and interest...
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
TW's Take: enough progress to lead to the creation of a new company focused on developing these therapeutics is a positive development. This is...
Alpha-Bet Soup
There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...
The Lows Appear To Be In Place
Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...
Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for...
TW's Take: Obviously not a positive, but I'm not concerned about this making it into the clinic eventually. It's a high-risk/high-reward program. The vast...
How Long Can You Hold A Soccer Ball Under Water?
Last week I wrote about INmune Bio (INMB). In that piece, In Defense of INmune, I discussed the increasing spread between perception of what's...
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
TW's Take: with Covid, and its various strands, destined to be here for a while, this is a nice development in a low cost...
A Catalyst Filled Quarter Lies Around The Corner
My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...
2nd Degree of Risk
Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...
This Week’s View On Anixa
A week in the market seems like an eternity these days, right?
I mean, just last week Anixa (ANIX) was trading at $8 a share....
Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
TW's Take: this IND filing has been years in the making, with Moffitt making many upgrades to the program. Success in solid tumors would...
Sitting On My Hands
My Investment Style...It's Not For Everyone But It Works For Me
I'm often asked why I don't trade more often. Many of my stocks make...
Technically Speaking
I've always thought that technical analysts were like lawyers; you can always find one who will tell you what you want to hear.
That said,...
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
TW's Take: 2021 is just getting started for Anixa which will launch trials of one vaccine program and expects to file an IND in...
Blood In The Water
Good Morning Vietnam!
Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...
Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy
TW's Take: important progress as Anixa gets ready to file their IND for this potentially blockbuster solid-tumor CAR-T therapy.
SAN JOSE, Calif., March 4, 2021...
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
TW's Take: with various strains of Covid-19 appearing, one could see the disease being here for many years and a therapeutic being greatly needed....
Heard On The Street
When I started in this business in the 1980s, "Heard on the Street" was a market moving column in the Wall Street Journal. R....
Riding the Waves
This is without a doubt the most amazing market of my career. It's obviously a bull market as indexes continue to head higher. But,...
The GameStop Impact…January In Review
What a crazy way to end a wild month, huh? As GameStop (GME) continued to rally in the face of shorts, Robin Hood required...
BOOM…Atomera Deal Highlights Another Bull Ride In The Market
Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...
Ho Ho Ho, Santa Rally Caps Bizarre Year
They say the best presents come in small packages, right? Well, Santa is delivering this year in a big way. And, the best gifts...
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast...
TW's Take: very exciting news for Anixa as the FDA not only accepted this IND filing but did so very quickly, a positive signal...
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious...
Climbing The Wall Of Worry…
That certainly was a crazy week. The news from our companies was positive, the news on the CoronaVirus was negative, volatility within our coverage...
The Micro-Cap Rally Continues Full Force
November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...
Anixa Adds An Ovarian Cancer Vaccine To Their Portfolio
Dr. Amit Kumar and Anixa Biosciences have added another potential jewel to their crown. With the licensing of a promising ovarian cancer vaccine from...
Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology
Tailwinds' Take: this expansion of Anixa's relationship with The Cleveland Clinic demonstrates the value of their partnership. Dr. Tuohy's group is a leader in...
Timing Is Everything…Or Is It?
The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
Tailwinds' Take: Yay! This long-awaited IND filing is game-changing for Anixa as it marks a significant milestone and brings them to the verge of...
The Biden Rally
As most of my readers know, I reserve Saturday mornings for writing my weekly newsletter. This week, however, Saturday morning marks the arrival of...
Sell Mortimer, Sell!!!
What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...
Anixa Biosciences to Host Conference Call to Provide Update on Programs
Tailwinds' Take: expecting to hear that an IND was filed for their breast cancer vaccine. Should be very positive.
SAN JOSE, Calif., Oct. 27, 2020...
Post Traumatic Investment Disease Redux? Nah, Just A Dose Of Reality
Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out...